Number of the records: 1
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF
- 1.
SYSNO ASEP 0191680 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF Author(s) Mikyšková, Romana (UMG-J) RID
Indrová, Marie (UMG-J) RID
Šímová, Jana (UMG-J) RID
Jandlová, Táňa (UMG-J)
Bieblová, Jana (UMG-J)
Jinoch, P. (CZ)
Bubeník, Jan (UMG-J)
Vonka, V. (CZ)Source Title International Journal of Oncology. - : Spandidos Publications - ISSN 1019-6439
Roč. 24, č. 1 (2004), s. 161-167Number of pages 7 s. Language eng - English Country GR - Greece Keywords HPV16 ; gene therapy ; minimal residual tumour disease Subject RIV FD - Oncology ; Hematology R&D Projects NC7148 GA MZd - Ministry of Health (MZ) NC7552 GA MZd - Ministry of Health (MZ) GA301/01/0985 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z5052915 - UMG-J Annotation Moderately immunogenic HPV16-associated tumours, MHC class I positive as well as negative, were used to examine the effects of local IL-2 and GM-CSF cytokine or gene therapy in the treatment of minimal residual tumour disease induced surgically or chemotherapeutically. Both types of neoplasms were found to be inhibited with adjuvant cytokine therapy. It is of interest to further investigate whether this is a general phenomenon in HPV16-associated tumour systems. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2004
Number of the records: 1